Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10777173 | 0.87 | ZDHHC7 (0.39) | CTSKCTSSCA1CA2 | |
| SCHEMBL2992403 | 0.85 | CTSS (0.34) | CTSKCTSS | |
| SCHEMBL1100608 | 0.79 | ALDH1A1 (0.36) | MEN1GAAKMT2A | |
| SCHEMBL1100758 | 0.79 | CA1 (0.41) | CA1CA2 | |
| SCHEMBL1070843 | 0.78 | HDAC1 (0.34) | — | |
| SCHEMBL9267217 | 0.77 | LMNA (0.30) | KMT2A | |
| SCHEMBL1788899 | 0.76 | LMNA (0.35) | — | |
| SCHEMBL7553021 | 0.76 | ZDHHC7 (0.35) | CA1CA2 | |
| SCHEMBL5916192 | 0.75 | CTSK (0.34) | CTSKCTSSCA1CA2NOS1 | |
| SCHEMBL9054275 | 0.75 | ALDH1A1 (0.44) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0011283-A1 | New lactyl tetrapeptide, processes for preparation thereof and pharmaceutical compositions containing it | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-28 | — | — | EP | claimed |
| EP-3259255-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | Theravance Biopharma R&D IP, LLC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-3256446-A1 | (2S, 4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | Theravance Biopharma R&D IP, LLC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-1373185-B1 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | AMINEX THERAPEUTICS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| WO-2016133803-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016130650-A1 | (2S, 4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-18 | — | — | WO | disclosed |
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8314087-B2 | Nitrogen-containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-6348463-B1 | Phenylalanine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2002-02-19 | — | — | US | disclosed |
| US-6319922-B1 | ALPHA-PYRIMIDYL-SUBSTITUTED; USEFUL FOR TREATING DISEASES INCLUDING INFLAMMATORY DISEASES, AND DISEASES INVOLVING ANGIOGENESIS, BONE RESORPTION OR CELLULAR OR MATRIX OVER-EXPANSION. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-11-20 | — | — | US | disclosed |
| US-20010034341-A1 | Ring opening metathesis of alkenes | CUNY GREGORY D (US) | 2001-10-25 | — | — | US | disclosed |
| WO-2001009093-A1 | BENZENAMINE DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| US-6177464-B1 | BACTERICIDES | SEPRACOR, INC. | 2001-01-23 | — | — | US | disclosed |
| EP-0966457-A1 | RING OPENING METATHESIS OF ALKENES | SEPRACOR, INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5889148-A | Antibiotic peptides | MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE (KR) | 1999-03-30 | — | — | US | disclosed |
| US-5843693-A | Assay method for screening for inhibitors of proTNF conversion | CHIRON CORPORATION (US) | 1998-12-01 | — | — | US | disclosed |
| WO-1998040373-A1 | RING OPENING METATHESIS OF ALKENES | SEPRACOR, INC. (US) | 1998-09-17 | — | — | WO | disclosed |
| WO-1997002286-A1 | NOVEL ANTIBIOTIC PEPTIDES | MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE (KR) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034341-A1 | Ring opening metathesis of alkenes | LSS, BAK1, LTC4S | CTSK 365/4885CTSS 263/4885CA1 3146/4885 |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | CTSK 1369/4885CTSS 620/4885CA1 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.